Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | GRB2 | P62993 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105435 | 0.91 | KLKB1 (0.53) | MMP1KLKB1 | |
| SCHEMBL1105429 | 0.89 | PSMB8 (0.50) | GRB2 | |
| SCHEMBL10042739 | 0.88 | ATM (0.53) | ATMANPEPGRB2KLKB1 | |
| SCHEMBL13058781 | 0.81 | PSMB5 (0.43) | GRB2MMP1 | |
| SCHEMBL10042737 | 0.78 | KLKB1 (0.55) | KLKB1CTSL | |
| SCHEMBL10042738 | 0.77 | PSMB8 (0.50) | GRB2 | |
| SCHEMBL31248331 | 0.77 | PSMB8 (0.50) | GRB2 | |
| SCHEMBL1109060 | 0.73 | SYK (0.50) | CTSL | |
| SCHEMBL4097560 | 0.71 | MMP13 (0.62) | ATMKLKB1CTSLCTSS | |
| SCHEMBL1109059 | 0.71 | SYK (0.47) | CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153596-B2 | Use of SH2 STAT3/STAT1 peptidomimetics as anticancer drugs | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090318367-A1 | Use of SH2 STAT3/STAT1 Peptidomimetics as Anticancer Drugs | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318367-A1 | Use of SH2 STAT3/STAT1 Peptidomimetics as Anticancer Drugs | STAT3, STAT1, STAT4 | ATM 2187/4885ANPEP 905/4885GRB2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.